ArticleInvestigational new drugs2021
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Jin-Ji Yang et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
55 papers cite it
this paperpooled ittrialcites it